Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Tim-4 antibody refers to a class of experimental monoclonal antibodies that target T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4), a transmembrane glycoprotein and phosphatidylserine receptor. TIM-4 is primarily expressed on antigen-presenting cells, such as tissue-resident macrophages and dendritic cells, where it plays a critical role in the engulfment of apoptotic cells (efferocytosis) and the regulation of T-cell proliferation. In oncology research, TIM-4+ macrophages have been identified as mediators of immune suppression within the tumor microenvironment. Blockade of TIM-4 using these antibodies has demonstrated the ability to enhance anti-tumor T-cell immunity and synergize with PD-1/PD-L1 checkpoint inhibitors in preclinical models of melanoma and colon cancer. While several research clones like RMT4-53 exist, the class remains in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Tim-4 antibody.